A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

Study Summary

The purpose of this study is to investigate the safety and tolerability of LY4298445 in healthy participants and in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). Participation in the study will last up to approximately 52 weeks.

Conditions

Healthy Systemic Lupus Erythematosus Rheumatoid Arthritis

Interventions / Drugs

LY4298445 LY4298445

View on ClinicalTrials.gov ↗

Sponsor

LLY

Eli Lilly and Company

Diabetes/Oncology

C53/100

Study Details

Enrollment63 participants

Primary Completion—

Lead SponsorEli Lilly and Company

Data Retrieved2026-04-11 02:55:33.866342+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.